Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Aug 7, 2017 • 4:01 PM EDT
Ligand Reports Second Quarter 2017 Financial Results
Jul 20, 2017 • 4:01 PM EDT
Ligand to Report Second Quarter 2017 Results on August 7th
Jul 17, 2017 • 9:00 AM EDT
Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330
Aug 7, 2017 • 4:30pm EDT
See all events
Jun 8, 2017 • 4:00pm EDT
New York, NY
May 31, 2017
Opthea presents additional positive data from OPT-302 Phase 1/2a Wet AMD trial at ASRS meeting https://t.co/RfB6mT4KF6
Melinta announces Cempra merger - forms leading commercial-stage anti-infectives company, focused on Baxdela launch https://t.co/9Vgyvx8lUf
Aldeyra announces that data from Phase 2a of ADX-102 in Dry Eye Disease (DED) is expected to be announced Sept '17 https://t.co/MWlcMXV7WS